Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.52 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.48 |
| ▸ | SKP1 | P63208 | 2/20 | 0.48 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.48 |
| ▸ | GBA1 | P04062 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402337 | 0.90 | MAP4K4 (0.52) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL2402237 | 0.84 | POLB (0.48) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL2400302 | 0.83 | PTPN11 (0.47) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL20507720 | 0.81 | MAP4K4 (0.48) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL18032579 | 0.81 | CKS1B (0.45) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL2402597 | 0.81 | NR1H2 (0.47) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL14782331 | 0.80 | MAP4K4 (0.57) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL2317966 | 0.80 | NEK2 (0.43) | PTPN11 | |
| SCHEMBL22712289 | 0.79 | KIT (0.47) | MAP4K4PTPN11CKS1BSKP1SKP2 | |
| SCHEMBL30323218 | 0.79 | KIT (0.47) | MAP4K4PTPN11CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700601-B2 | Substituted indazoles of formula 1.0 that are kinase inhibitors | SCHERING CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | SCHERING CORPORATION | 2008-01-24 | — | — | US | disclosed |
| US-6894050-B2 | 5-HT receptor ligands and uses thereof | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-04-28 | — | — | US | disclosed |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090503-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | MAP4K4 3156/4885PTPN11 3966/4885CKS1B 4756/4885 |
| US-20050020604-A1 | 5-HT receptor ligands and uses thereof | HTR2A, HTR1A, HTR5A | MAP4K4 3156/4885PTPN11 3966/4885CKS1B 4756/4885 |
| US-20080021019-A1 | immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease; substituted pyrazine compounds | BRCA1, PDK2, PDK1 | MAP4K4 142/4885PTPN11 1535/4885CKS1B 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.